Atika Capital Management buys $8,271,705 stake in Nevro Corp (NVRO)

Nevro Corp (NVRO) : Atika Capital Management scooped up 21,844 additional shares in Nevro Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 84,500 shares of Nevro Corp which is valued at $8,271,705.Nevro Corp makes up approximately 4.12% of Atika Capital Management’s portfolio.

Other Hedge Funds, Including , Manufacturers Life Insurance Company The boosted its stake in NVRO in the latest quarter, The investment management firm added 399 additional shares and now holds a total of 11,408 shares of Nevro Corp which is valued at $1,116,729.Seven Eight Capital reduced its stake in NVRO by selling 2,900 shares or 76.32% in the most recent quarter. The Hedge Fund company now holds 900 shares of NVRO which is valued at $88,101. Nevro Corp makes up approx 0.03% of Seven Eight Capital’s portfolio. Pacad Investment Ltd. added NVRO to its portfolio by purchasing 8,900 company shares during the most recent quarter which is valued at $871,221. Nevro Corp makes up approx 0.12% of Pacad Investment Ltd.’s portfolio.Timpani Capital Management boosted its stake in NVRO in the latest quarter, The investment management firm added 21,038 additional shares and now holds a total of 35,381 shares of Nevro Corp which is valued at $3,463,446. Nevro Corp makes up approx 1.38% of Timpani Capital Management’s portfolio.California State Teachers Retirement System boosted its stake in NVRO in the latest quarter, The investment management firm added 15,167 additional shares and now holds a total of 50,474 shares of Nevro Corp which is valued at $4,139,877. Nevro Corp makes up approx 0.01% of California State Teachers Retirement System’s portfolio.

Nevro Corp opened for trading at $94.61 and hit $97.22 on the upside on Thursday, eventually ending the session at $96.02, with a gain of 1.68% or 1.59 points. The heightened volatility saw the trading volume jump to 3,85,300 shares. Company has a market cap of $2,737 M.

On the company’s financial health, Nevro Corp reported $-0.31 EPS for the quarter, beating the analyst consensus estimate by $ 0.16 according to the earnings call on Aug 8, 2016. Analyst had a consensus of $-0.47. The company had revenue of $55.40 million for the quarter, compared to analysts expectations of $44.98 million. The company’s revenue was up 385.5% compared to the same quarter last year.

Many Wall Street Analysts have commented on Nevro Corp. BofA/Merrill Initiated Nevro Corp on Aug 8, 2016 to “Buy”, Price Target of the shares are set at $100.Nevro Corp was Initiated by Piper Jaffray to “Overweight” on Jul 22, 2016. Nevro Corp was Initiated by Wells Fargo to “Outperform” on Jul 12, 2016.

Nevro Corp. is a medical device company. The Company manufactures and markets active implantable medical devices for the treatment of neurological disorders initially focusing on the treatment of chronic pain. The Company developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is the only spinal cord stimulation (SCS) system that delivers its HF10 therapy. The Company’s Senza system creates electrical impulses from two hertz to 10 kilohertz including its HF10 therapy which allows for pain relief without paresthesia. HF10 therapy delivers waveforms at 10 kilohertz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads a trial stimulator an implantable pulse generator (IPG) surgical tools a clinician laptop programmer a patient remote control and a mobile charger.

Leave a Reply

Nevro Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Nevro Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.